Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) has announced its quarterly earnings conference call for Q4 2021, scheduled on January 27, 2022, at 8:00 a.m. ET. The call will last around 1 hour and will be accessible via a live webcast on Danaher’s website under the 'Investors' section. A replay will be available after the event. Interested parties can join the call by dialing 800-895-3361 (U.S.) or +1 785-424-1062 (internationally) before the start time. The earnings press release and related materials will be posted online at 6:00 a.m. ET on the same day.
Danaher Corporation (NYSE: DHR) has announced a regular quarterly cash dividend of $0.21 per share on common stock, payable on January 28, 2022, to shareholders of record on December 30, 2021. Additionally, the Board approved a quarterly cash dividend of $11.875 per share of its 4.75% Series A Preferred Stock and $12.50 per share of its 5.00% Series B Preferred Stock, both payable on January 15, 2022, to holders of record on December 31, 2021.
Danaher Corporation (NYSE: DHR) has priced an offering of $1 billion in 2.800% senior notes due 2051, with an offering price set at 99.396% of the principal amount. The expected net proceeds are approximately $984 million, intended for redeeming all outstanding 2.500% senior notes due 2025, refinancing debt, working capital, and other corporate purposes. The offering is anticipated to close on December 10, 2021, subject to customary conditions. This move is part of Danaher's strategy to manage its debt efficiently.
IDBS, a Danaher operating company, launched Polar Insight, enhancing its BioPharma Lifecycle Management (BPLM) platform with advanced data analytics and visualization tools. This innovation replaces outdated manual processes, allowing for integrated digital workflows that streamline data handling from development to manufacturing. The new capabilities aim to accelerate innovation and regulatory filings, enabling clients to deliver vaccines and therapies more efficiently. The first dashboards will be available in Q1 2022.
Danaher Corporation (NYSE:DHR) will redeem €800,000,000 of 2.500% Senior Notes due 2025. The redemption price includes the principal amount, a make-whole premium, and accrued interest. This action will occur on December 29, 2021. Danaher is a global technology innovator in health care and environmental markets, committed to solving complex challenges. With over 69,000 associates, the company maintains a strong operational culture based on the Danaher Business System.
Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, present at the Evercore ISI HealthCONx Conference on December 1, 2021, at 1:00 p.m. ET. The presentation will be webcast live on www.danaher.com. Danaher is a leader in science and technology, dedicated to solving complex challenges in health care, environmental, and applied markets, with around 69,000 associates globally. For further details, visit their website.
Danaher Corporation (NYSE: DHR) reported strong third-quarter results for 2021, achieving net earnings of $1.2 billion or $1.54 per diluted share, marking a 33% YoY increase. Revenues surged 23% YoY to $7.2 billion, with non-GAAP core revenue growth of 20.5%. The company also noted significant increases in operating cash flow and free cash flow, up 51% and 46.5% YoY, respectively. Looking ahead, Danaher expects non-GAAP core revenue growth in the low-to-mid teens for Q4 and over 20% for the full year 2021. The recent acquisition of Aldevron is set to bolster its genomic medicine capabilities.
Summary not available.
Beckman Coulter has launched the DxU Iris Workcell, an automated urinalysis system, at the AACC Annual Scientific Meeting on September 28, 2021. This innovative system reduces manual reviews to 4% and minimizes workflow disruptions in laboratories. The DxU Iris Workcell integrates advanced technology for enhanced accuracy and standardization in urinalysis, addressing increased laboratory demands, especially post-pandemic. It features a Load and Unload station for managing 190 samples and is designed for high-volume laboratories, promoting faster turnaround times and improved laboratory efficiency.
Danaher Corporation (NYSE: DHR) will host its third quarter 2021 earnings conference call on October 21, 2021, at 8:00 a.m. ET. The call will last about one hour and will be available via webcast on Danaher's website. A replay will follow shortly after and remain accessible until November 4, 2021. The earnings press release and presentation materials will be posted at 6:00 a.m. ET on the same day.
Danaher focuses on science and technology solutions, impacting healthcare and environmental sectors with over 69,000 associates.